FY2027 Earnings Forecast for Omeros Issued By HC Wainwright

Omeros Corporation (NASDAQ:OMER) – Investment analysts at HC Wainwright lowered their FY2027 earnings per share estimates for shares of Omeros in a research report issued on Friday, June 26th. HC Wainwright analyst B. Folkes now expects that the biopharmaceutical company will earn $0.07 per share for the year, down from their previous estimate of $0.32. HC Wainwright has a “Buy” rating and a $33.00 price target on the stock. The consensus estimate for Omeros’ current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Omeros’ FY2028 earnings at $2.14 EPS, FY2029 earnings at $3.95 EPS and FY2030 earnings at $5.00 EPS.

Other research analysts have also recently issued research reports about the stock. D. Boral Capital restated a “buy” rating and issued a $36.00 price objective on shares of Omeros in a report on Tuesday, April 21st. Zacks Research upgraded shares of Omeros from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 2nd. Weiss Ratings cut shares of Omeros from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, June 2nd. Finally, Wall Street Zen downgraded shares of Omeros from a “buy” rating to a “hold” rating in a research note on Sunday, June 7th. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Omeros presently has an average rating of “Moderate Buy” and an average price target of $38.00.

Omeros Stock Performance

Shares of OMER opened at $9.91 on Tuesday. The stock has a market capitalization of $717.24 million, a PE ratio of 14.16 and a beta of 2.52. Omeros has a 1 year low of $2.95 and a 1 year high of $17.65. The company’s 50-day simple moving average is $11.84 and its 200-day simple moving average is $11.85.

Omeros (NASDAQ:OMER) last released its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.16. The firm had revenue of $9.89 million during the quarter, compared to analyst estimates of $4.19 million.

Institutional Trading of Omeros

A number of large investors have recently made changes to their positions in OMER. UBS Group AG grew its holdings in Omeros by 213.5% during the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock worth $38,180,000 after acquiring an additional 1,513,893 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Omeros by 1,201.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 416,153 shares of the biopharmaceutical company’s stock valued at $1,706,000 after purchasing an additional 384,168 shares during the last quarter. Corient Private Wealth LLC raised its holdings in shares of Omeros by 13.0% in the 4th quarter. Corient Private Wealth LLC now owns 688,025 shares of the biopharmaceutical company’s stock valued at $11,817,000 after purchasing an additional 79,263 shares in the last quarter. AlphaQuest LLC raised its holdings in shares of Omeros by 8,259,600.0% in the 4th quarter. AlphaQuest LLC now owns 82,597 shares of the biopharmaceutical company’s stock valued at $1,419,000 after purchasing an additional 82,596 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Omeros by 19.9% during the 4th quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock worth $68,929,000 after purchasing an additional 666,357 shares during the last quarter. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Omeros

In other news, Director Thomas J. Cable sold 7,500 shares of Omeros stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $11.61, for a total value of $87,075.00. Following the completion of the transaction, the director owned 35,067 shares in the company, valued at approximately $407,127.87. This trade represents a 17.62% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.50% of the stock is owned by corporate insiders.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.